Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma
Hu, Dingyuan LU ; Ansari, Daniel LU ; Zhou, Qimin LU
; Sasor, Agata
LU
; Said Hilmersson, Katarzyna
LU
and Andersson, Roland
LU
(2019)
In Scandinavian Journal of Gastroenterology
54(1).
p.95-100
- Abstract
Background: Galectins are a group of carbohydrate-binding proteins that are involved in neoplastic development and progression. In a previous mass spectrometry-based study, we identified galectin 4 as a down-regulated protein in short-term survivors of pancreatic cancer. This study was performed to validate the prognostic value of galectin 4 in a larger cohort of pancreatic cancer patients undergoing surgical resection. Methods: Galectin 4 expression was evaluated by tissue microarrays and immunohistochemistry in 140 patients with surgically resected pancreatic cancer. Kaplan-Meier and Cox proportional hazards modeling were used to explore the association between galectin 4 and survival. Results: Galectin 4 staining expression was... (More)
Background: Galectins are a group of carbohydrate-binding proteins that are involved in neoplastic development and progression. In a previous mass spectrometry-based study, we identified galectin 4 as a down-regulated protein in short-term survivors of pancreatic cancer. This study was performed to validate the prognostic value of galectin 4 in a larger cohort of pancreatic cancer patients undergoing surgical resection. Methods: Galectin 4 expression was evaluated by tissue microarrays and immunohistochemistry in 140 patients with surgically resected pancreatic cancer. Kaplan-Meier and Cox proportional hazards modeling were used to explore the association between galectin 4 and survival. Results: Galectin 4 staining expression was positive in 111 cases (79.3%). The expression of galectin 4 was significantly associated with tumor size (p =.008) and differentiation (p =.001). Galectin 4 expression was significantly correlated with disease recurrence within 1 year of surgery (adjusted HR 0.485, p =.027). There was also a significant association between galectin 4 and overall survival at 1 year (adjusted HR 0.482, p =.047) and at 3 years (adjusted HR 0.550, p =.025). Conclusion: Galectin 4 expression is a novel biomarker for early recurrence and mortality after surgical resection for pancreatic cancer.
(Less)
- author
- Hu, Dingyuan
LU
; Ansari, Daniel
LU
; Zhou, Qimin
LU
; Sasor, Agata
LU
; Said Hilmersson, Katarzyna
LU
and Andersson, Roland
LU
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- early recurrence, galectin 4, LGALS4, Pancreatic cancer, survival
- in
- Scandinavian Journal of Gastroenterology
- volume
- 54
- issue
- 1
- pages
- 6 pages
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85060337778
- pmid:30663442
- ISSN
- 0036-5521
- DOI
- 10.1080/00365521.2018.1561937
- language
- English
- LU publication?
- yes
- id
- d77d209a-9d25-494a-b434-3903dbd85380
- alternative location
- https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060337778&doi=10.1080%2f00365521.2018.1561937&partnerID=40&md5=81cedb9036d51fd434bbd6b3c8a16f44
- date added to LUP
- 2019-02-01 09:54:18
- date last changed
- 2024-03-19 00:22:53
@article{d77d209a-9d25-494a-b434-3903dbd85380,
abstract = {{<p>Background: Galectins are a group of carbohydrate-binding proteins that are involved in neoplastic development and progression. In a previous mass spectrometry-based study, we identified galectin 4 as a down-regulated protein in short-term survivors of pancreatic cancer. This study was performed to validate the prognostic value of galectin 4 in a larger cohort of pancreatic cancer patients undergoing surgical resection. Methods: Galectin 4 expression was evaluated by tissue microarrays and immunohistochemistry in 140 patients with surgically resected pancreatic cancer. Kaplan-Meier and Cox proportional hazards modeling were used to explore the association between galectin 4 and survival. Results: Galectin 4 staining expression was positive in 111 cases (79.3%). The expression of galectin 4 was significantly associated with tumor size (p =.008) and differentiation (p =.001). Galectin 4 expression was significantly correlated with disease recurrence within 1 year of surgery (adjusted HR 0.485, p =.027). There was also a significant association between galectin 4 and overall survival at 1 year (adjusted HR 0.482, p =.047) and at 3 years (adjusted HR 0.550, p =.025). Conclusion: Galectin 4 expression is a novel biomarker for early recurrence and mortality after surgical resection for pancreatic cancer.</p>}},
author = {{Hu, Dingyuan and Ansari, Daniel and Zhou, Qimin and Sasor, Agata and Said Hilmersson, Katarzyna and Andersson, Roland}},
issn = {{0036-5521}},
keywords = {{early recurrence; galectin 4; LGALS4; Pancreatic cancer; survival}},
language = {{eng}},
number = {{1}},
pages = {{95--100}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Gastroenterology}},
title = {{Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma}},
url = {{http://dx.doi.org/10.1080/00365521.2018.1561937}},
doi = {{10.1080/00365521.2018.1561937}},
volume = {{54}},
year = {{2019}},
}